Compare Motorola Solutions Inc (MSI) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Motorola Solutions Inc vs Zimmer Biomet Holdings Inc — how do they compare? Motorola Solutions Inc trades at $444.71 (market cap $74.00B), while Zimmer Biomet Holdings Inc trades at $89.8 (market cap $16.95B). The key difference: Motorola Solutions Inc is far larger — about 4.4× Zimmer Biomet Holdings Inc's market cap, and Motorola Solutions Inc is trading nearer its 52-week high, Zimmer Biomet Holdings Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Motorola Solutions Inc for 100 Days and Zimmer Biomet Holdings Inc for 89 Days on average.
| MSI | ZBH | |
|---|---|---|
Market Cap | $74.00B | $16.95B |
Volume | 722,147 | 2,505,240 |
Sector | Technology | Health |
52-Week High | $491.24 | $103.98 |
52-Week Low | $363.83 | $79.58 |
Typical Hold Time | 100 Days | 89 Days |
Enterprise Value | $82.90B | $24.02B |
Dividend Yield | 1.08% | 1.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Motorola Solutions (MSI) trades at $448.48, down 1.72% on the day, amid a bearish technical signal. The company shows strong fundamentals with revenue growth to $11.68B in 2025 and a record $15.6B backlog. Recent acquisitions like D-Fend Solutions and a $139M Louisiana public safety contract highlight expansion in security and AI-driven solutions. Earnings have consistently beaten estimates, with Q2 2026 EPS of $4.41 surpassing the $3.85 expectation. However, cash flow trends show significant investing outflows for growth initiatives.
The outlook remains positive given analyst consensus with a $525.86 price target and 70.59% buy ratings, though risks include high valuation multiples and increased debt levels from acquisitions. The stock's current bearish technical stance may present a buying opportunity if fundamentals continue to strengthen, but investors should monitor cash flow sustainability and integration of recent purchases.
Zimmer Biomet (ZBH) trades at $88.49, down 1.33% today, with a bearish technical signal from moving averages. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $2.07 surpassing the $2.01 estimate. Revenue growth is steady, reaching $8.23B in 2025, though net income margin has moderated to 9.48%. A quarterly dividend of $0.24 was declared, payable in October 2026. Analyst consensus price target is $103.11, implying potential upside from current levels.
The outlook is mixed: solid fundamentals and earnings momentum support long-term value, but technical weakness and elevated debt levels pose near-term risks. Investment appeal hinges on execution of commercial transformation and robotics adoption offsetting competitive pressures. Key risks include margin compression and macroeconomic sensitivity affecting procedure volumes.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Motorola Solutions Inc
Motorola Solutions, Inc. is a data communications and telecommunications equipment provider. The Company develops data capture, wireless, infrastructure, bar code scanning, two-way radios, and wireless broadband networks. Motorola also produces public safety and government products, voice and data communications products and systems, and wireless LAN securities.
Read more on MSI →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
